4//SEC Filing
THURMAN RANDY H 4
Accession 0001209191-20-053870
CIK 0001649989other
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 6:44 PM ET
Size
8.3 KB
Accession
0001209191-20-053870
Insider Transaction Report
Form 4
THURMAN RANDY H
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-10-01+259,297→ 259,297 totalExercise: $0.71Exp: 2030-10-01→ Common Stock (259,297 underlying) - Award
Stock Option (Right to Buy)
2020-10-05$0.51/sh+396,809$204,000→ 396,809 totalExercise: $0.71Exp: 2030-10-05→ Common Stock (396,809 underlying)
Footnotes (2)
- [F1]The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.
- [F2]The options were granted under the 2015 Plan in lieu of $204,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
Related Parties
1- filerCIK 0001204059
Filing Metadata
- Form type
- 4
- Filed
- Oct 4, 8:00 PM ET
- Accepted
- Oct 5, 6:44 PM ET
- Size
- 8.3 KB